Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones
- PMID: 10933654
- DOI: 10.1093/jac/46.2.283
Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones
Abstract
The in vitro activities of mupirocin, quinupristin/dalfopristin, linezolid, eperezolid, sitafloxacin, clinafloxacin, moxifloxacin, amoxycillin, metronidazole and clarithromycin were tested at pH 7.4 against 57 strains of Helicobacter pylori. The most active agents (mupirocin, sitafloxacin and clinafloxacin) were also tested for activity at pH 5.4 against the same strains. Mupirocin was very active at pH 7.4 and 5.4 (MIC90 0.25 and 0.12 mg/L, respectively). Quinupristin/dalfopristin, linezolid and eperezolid had low activity (MIC90 4, 8 and 4 mg/L, respectively). Sitafloxacin (MIC90 </= 0.008 mg/L) was the most active fluoroquinolone, while clinafloxacin (MIC90 0.12 mg/L) and moxifloxacin (MIC90 2 mg/L) were least active.
Similar articles
-
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569. J Antimicrob Chemother. 1999. PMID: 10350389
-
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001. Antimicrob Agents Chemother. 2001. PMID: 11502536 Free PMC article.
-
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.Indian J Med Res. 2004 Dec;120(6):546-52. Indian J Med Res. 2004. PMID: 15654141
-
A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.J Antimicrob Chemother. 1997 May;39 Suppl A:59-62. doi: 10.1093/jac/39.suppl_1.59. J Antimicrob Chemother. 1997. PMID: 9511064 Review.
-
Treatment options for vancomycin-resistant enterococcal infections.Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002. Drugs. 2002. PMID: 11827558 Review.
Cited by
-
Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery.Obes Surg. 2013 Feb;23(2):145-9. doi: 10.1007/s11695-012-0747-4. Obes Surg. 2013. PMID: 23054570
-
Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.BMC Gastroenterol. 2009 May 26;9:38. doi: 10.1186/1471-230X-9-38. BMC Gastroenterol. 2009. PMID: 19470177 Free PMC article. Clinical Trial.
-
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.Dig Dis Sci. 2015 Feb;60(2):458-64. doi: 10.1007/s10620-014-3365-2. Epub 2014 Sep 19. Dig Dis Sci. 2015. PMID: 25236423
-
Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.Antimicrob Agents Chemother. 2003 Dec;47(12):3942-4. doi: 10.1128/AAC.47.12.3942-3944.2003. Antimicrob Agents Chemother. 2003. PMID: 14638505 Free PMC article.
-
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.Antimicrob Agents Chemother. 2009 Apr;53(4):1720-1. doi: 10.1128/AAC.00049-09. Epub 2009 Feb 2. Antimicrob Agents Chemother. 2009. PMID: 19188389 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical